298 related articles for article (PubMed ID: 1847845)
1. Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.
Sasaki Y; Shinkai T; Eguchi K; Tamura T; Ohe Y; Ohmori T; Saijo N
Cancer Chemother Pharmacol; 1991; 27(4):263-70. PubMed ID: 1847845
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacological approach to the platinum compounds].
Sasaki Y
Gan To Kagaku Ryoho; 1992 Apr; 19(4):456-62. PubMed ID: 1313667
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.
Fukuda M; Ohe Y; Kanzawa F; Oka M; Hara K; Saijo N
Anticancer Res; 1995; 15(2):393-8. PubMed ID: 7763011
[TBL] [Abstract][Full Text] [Related]
4. In vitro cytotoxicity, pharmacokinetics and ex vivo pharmacodynamics of a new platinum compound, cis-malonato [(4R,5R-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclopentane] platinum (II).
Kim DK; Kim HT; Cho YB; Kim TS; Kim KH; Hong WS
Anticancer Res; 1996; 16(1):251-6. PubMed ID: 8615617
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of carboplatin (CBDCA) in small-cell and non-small-cell lung cancer with correlation to in vitro analysis of cytotoxicity.
Dmitrovsky E; Seifter EJ; Gazdar AF; Tsai CM; Edison M; Brantley P; Veach SR; Batist G; Ihde DC; Mulshine JL
Am J Clin Oncol; 1990 Aug; 13(4):285-9. PubMed ID: 2165737
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of a new platinum compound (glycolate-o,o') diammineplatinum (II) (254-S), against non-small cell lung carcinoma grown in a human tumor clonogenic assay system.
Kanzawa F; Matsushima Y; Nakano H; Nakagawa K; Takahashi H; Sasaki Y; Saijo N
Anticancer Res; 1988; 8(3):323-7. PubMed ID: 2839098
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of the antitumor activity of newly developed platinum analogs in lung cancer using the colony assay].
Yonei T; Ohnoshi T; Hiraki S; Ueoka H; Yamashita H; Kozuka A; Moritaka T; Uji H; Kiura K; Mima Y
Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 1):427-30. PubMed ID: 2539056
[No Abstract] [Full Text] [Related]
8. Antitumor activity of platinum analogs against human lung cancer cell lines and tumor specimens.
Yonei T; Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Moritaka T; Shibayama T; Tabata M; Segawa Y; Takigawa N
Acta Med Okayama; 1993 Aug; 47(4):233-41. PubMed ID: 8213217
[TBL] [Abstract][Full Text] [Related]
9. Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin.
Tang CH; Parham C; Shocron E; McMahon G; Patel N
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1389-400. PubMed ID: 20809122
[TBL] [Abstract][Full Text] [Related]
10. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.
Alberts DS; Fanta PT; Running KL; Adair LP; Garcia DJ; Liu-Stevens R; Salmon SE
Cancer Chemother Pharmacol; 1997; 39(6):493-7. PubMed ID: 9118460
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin.
Twentyman PR; Wright KA; Mistry P; Kelland LR; Murrer BA
Cancer Res; 1992 Oct; 52(20):5674-80. PubMed ID: 1327513
[TBL] [Abstract][Full Text] [Related]
12. Small cell lung cancer: defining a role for emerging platinum drugs.
Schiller JH
Oncology; 2002; 63(2):105-14. PubMed ID: 12239444
[TBL] [Abstract][Full Text] [Related]
13. In vitro colony inhibition of carboplatin against stomach and lung cancer cell lines in comparison with cisplatin.
Takahashi H; Sasaki Y; Saijo N; Sakurai M; Nakano H; Nakagawa K; Hoshi A; Jett JR; Hong WS
Cancer Chemother Pharmacol; 1987; 19(3):197-200. PubMed ID: 3034444
[TBL] [Abstract][Full Text] [Related]
14. Review of therapeutic trials of carboplatin in lung cancer.
Bunn PA
Semin Oncol; 1989 Apr; 16(2 Suppl 5):27-33. PubMed ID: 2541506
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and antitumor activity of a new platinum compound, cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1, 3- dioxolane]platinum(II), as determined by ex vivo pharmacodynamics.
Kim DK; Kim HT; Tai JH; Cho YB; Kim TS; Kim KH; Park JG; Hong WS
Cancer Chemother Pharmacol; 1995; 37(1-2):1-6. PubMed ID: 7497577
[TBL] [Abstract][Full Text] [Related]
16. In vivo screening models of cisplatin-resistant human lung cancer cell lines using SCID mice.
Heike Y; Takahashi M; Ohira T; Arioka H; Funayama Y; Nishio K; Ogasawara H; Saijo N
Cancer Chemother Pharmacol; 1995; 35(3):200-4. PubMed ID: 7805177
[TBL] [Abstract][Full Text] [Related]
17. Platinum compounds in the treatment of advanced breast cancer.
MartÃn M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
18. Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines.
Groen HJ; Sleijfer S; Meijer C; Kampinga HH; Konings AW; De Vries EG; Mulder NH
Br J Cancer; 1995 Dec; 72(6):1406-11. PubMed ID: 8519652
[TBL] [Abstract][Full Text] [Related]
19. Levels of glutathione S transferase pi mRNA in human lung cancer cell lines correlate with the resistance to cisplatin and carboplatin.
Nakagawa K; Yokota J; Wada M; Sasaki Y; Fujiwara Y; Sakai M; Muramatsu M; Terasaki T; Tsunokawa Y; Terada M
Jpn J Cancer Res; 1988 Mar; 79(3):301-4. PubMed ID: 2836347
[TBL] [Abstract][Full Text] [Related]
20. [Development of platinum analogues for the treatment of lung cancer].
Nakai Y
Gan To Kagaku Ryoho; 1992 Nov; 19(13):2157-62. PubMed ID: 1332625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]